Adagene (ADAG) announced that the U.S. Food and Drug Administration, FDA, has designated muzastotug, in combination with Merck’s (MRK) anti-PD-1 therapy, KEYTRUDA, as a Fast Track product for adult patients with microsatellite stable metastatic colorectal cancer, MSS mCRC, without current or active liver metastases. Muzastotug is a next-generation masked anti-CTLA-4 SAFEbody engineered to overcome CTLA-4-mediated Treg resistance in tumors with enhanced safety and efficacy, delivering a therapeutic index beyond the reach of existing CTLA-4 therapies.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADAG:
- Adagene initiated with a Buy at Guggenheim on muzastotug potential
- Adagene initiated with a Buy at Guggenheim
- Adagene initiated with an Outperform at LifeSci Capital
- Adagene and Third Arc Bio Forge Licensing Agreement for Cancer Therapy Development
- Adagene announces licensing agreement with Third Arc Bio